James S. Duncan

发表

Mathematical Methods in Medical Imaging III: 25-26 July, 1994, San Diego, California

David C. Wilson, Fred L. Bookstein, Nicholas Lange, 1994 .

James S. Duncan, David C. Wilson, Fred L. Bookstein, 1992 .

Abstract 1731: Preclinical testing demonstrates strong activity of STA-12-8666, an HSP90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)

James S. Duncan, A. Gaponova, A. Nikonova, 2015 .

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

James S. Duncan, Samantha M. Miller, P. Kuan, 2015, Cell reports.

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

Jian Jin, Charles M. Perou, Katherine A. Hoadley, 2012, Cell.

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

James S. Duncan, C. Perou, David B. Darr, 2012, Clinical Cancer Research.

An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics

James S. Duncan, David W. Litchfield, T. Haystead, 2008, Molecular & Cellular Proteomics.

Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2.

James S. Duncan, D. Litchfield, D. Shugar, 2005, Biochimica et biophysica acta.

Phosphorylation of RIAM by Src Promotes Integrin Activation by Unmasking the PH Domain of RIAM.

James S. Duncan, Vikas Kumar, Eun-Ah Cho, 2020, Structure.

Peptide biosensors for the electrochemical measurement of protein kinase activity.

James S. Duncan, K. Kerman, D. Litchfield, 2008, Analytical chemistry.

Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target

James S. Duncan, G. Mantia-Smaldone, Vikas Kumar, 2020, Molecular & Cellular Proteomics.

Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma

James S. Duncan, J. Chernoff, G. Mantia-Smaldone, 2020, Science Signaling.

Multiplex-inhibitor bead mass spectrometry reveals differential kinome signatures in newly diagnosed and recurrent glioblastoma

James S. Duncan, J. Sarkaria, Anna Jermakowicz, 2020 .

PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers centrosome destabilization

James S. Duncan, C. Lindskog, A. Nikonova, 2019, Oncogenesis.

A Peptide-Based Target Screen Implicates the Protein Kinase CK2 in the Global Regulation of Caspase Signaling

James S. Duncan, G. Gloor, S. Li, 2011, Science Signaling.

Extracellular 5′-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins

James S. Duncan, S. Gupta, H. Lee, 2022, The Journal of biological chemistry.

The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells

James S. Duncan, J. Testa, A. Bellacosa, 2022, Science Signaling.

Protein kinase CK2 is a constitutively active enzyme that promotes cell survival: strategies to identify CK2 substrates and manipulate its activity in mammalian cells.

James S. Duncan, D. Litchfield, Nicole A St Denis, 2010, Methods in enzymology.

Discoidin Domain Receptor 1 (DDR1) tyrosine kinase is upregulated in PKD kidneys but does not play a role in the pathogenesis of polycystic kidney disease

James S. Duncan, E. Skolnik, I. Soomro, 2019, PloS one.

Discoidan Domain Receptor 1 (DDR1) Tyrosine Kinase is Upregulated in PKD Kidneys But Does Not Play a Role in the Pathogenesis of Polycystic Kidney Disease

James S. Duncan, E. Skolnik, I. Soomro, 2019, bioRxiv.

Unbiased Functional Proteomics Strategy for Protein Kinase Inhibitor Validation and Identification of bona fide Protein Kinase Substrates: Application to Identification of EEF1D as a Substrate for CK2

James S. Duncan, D. Litchfield, M. Bretner, 2011, Journal of proteome research.

Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.

James S. Duncan, S. Li, G. Lajoie, 2008, Cellular signalling.

Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

James S. Duncan, D. Litchfield, 2008, Biochimica et biophysica acta.

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.

James S. Duncan, J. R. Peterson, Kelly E. Duncan, 2016, Cell reports.

Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Malignant Mesothelioma

James S. Duncan, J. Testa, Yinfei Tan, 2020, bioRxiv.

NetrinG1+ Cancer-Associated Fibroblasts Generate Unique Extracellular Vesicles that Support the Survival of Pancreatic Cancer Cells Under Nutritional Stress

James S. Duncan, L. Languino, E. Cukierman, 2021, bioRxiv.

The dynamic nature of the kinome.

James S. Duncan, L. Graves, G. Johnson, 2013, The Biochemical journal.

Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target

James S. Duncan, G. Mantia-Smaldone, Vikas Kumar, 2020, Molecular & Cellular Proteomics.

Regulation of caspase pathways by protein kinase CK2: identification of proteins with overlapping CK2 and caspase consensus motifs

James S. Duncan, G. Gloor, D. Litchfield, 2011, Molecular and Cellular Biochemistry.

Regulation of cell proliferation and survival: convergence of protein kinases and caspases.

James S. Duncan, G. Gloor, S. Li, 2010, Biochimica et biophysica acta.

A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer

James S. Duncan, A. Gaponova, A. Nikonova, 2016, Clinical Cancer Research.

Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP.

James S. Duncan, T. Haystead, D. Litchfield, 2012, Methods in molecular biology.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

James S. Duncan, Steven P. Angus, C. Perou, 2017, Cancer discovery.

Defining the expressed breast cancer kinome

James S. Duncan, L. Carey, S. Gomez, 2012, Cell Research.

Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment

James S. Duncan, Yan Zhou, M. Einarson, 2020, JCI insight.

Identification of Wee1 as Target in Combination with Avapritinib for the Treatment of Gastrointestinal Stromal Tumor

James S. Duncan, Yan Zhou, M. Einarson, 2020, bioRxiv.

Kinome Profiling of Gastrointestinal Stromal Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies Wee1 as Candidate Therapeutic Target

James S. Duncan, Yan Zhou, M. Einarson, 2020 .

Intrinsic Resistance to MEK Inhibition through BET Protein–Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer

James S. Duncan, Kelly E. Duncan, J. Chernoff, 2019, Molecular Cancer Research.

FAM122A ensures cell cycle interphase progression and checkpoint control as a SLiM-dependent substrate-competitive inhibitor to the B55⍺/PP2A phosphatase

James S. Duncan, R. Dunbrack, Qifang Xu, 2023, bioRxiv.

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

James S. Duncan, Daniel G. Araiza, Carlos Herrera-Montávez, 2021, bioRxiv.

Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia

James S. Duncan, S. Frye, R. Christopherson, 2013, PloS one.

Cancer Therapy : Preclinical Combined PI 3 K / mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

James S. Duncan, C. Perou, David B. Darr, 2012 .

MEK1/2-Targeting PROTACs Promote the Collateral Degradation of CRAF in KRAS Mutant Cells

James S. Duncan, Carlos Herrera-Montávez, Alison M. Kurimchak, 2023, bioRxiv.

FAM122A ensures cell cycle interphase progression and checkpoint control as a SLiM-dependent substrate-competitive inhibitor to the B55⍺/PP2A phosphatase

James S. Duncan, R. Dunbrack, Qifang Xu, 2023, bioRxiv.

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

James S. Duncan, Yan Zhou, J. Chernoff, 2023, bioRxiv.

Protein kinase CK2 is a constitutively active enzyme that promotes cell survival: strategies to identify CK2 substrates and manipulate its activity in mammalian cells.

James S. Duncan, D. Litchfield, Nicole A St Denis, 2010, Methods in enzymology.